Tisdag 13 Maj | 07:46:19 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-12 08:00 Bokslutskommuniké 2025
2025-11-06 08:00 Kvartalsrapport 2025-Q3
2025-08-21 08:00 Kvartalsrapport 2025-Q2
2025-05-16 N/A X-dag ordinarie utdelning ACARIX 0.00 SEK
2025-05-15 N/A Årsstämma
2025-05-12 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Extra Bolagsstämma 2024
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-09-28 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-12-09 - Extra Bolagsstämma 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-23 - Extra Bolagsstämma 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-08-16 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 - Årsstämma
2018-05-23 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Idag innehas verksamhet främst inom den nordiska marknaden. Bolaget grundades under 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.
2025-05-12 08:00:00

Acarix, a leader in rapid AI and acoustics-based cardiac diagnostics, today announced its interim financial results for the first quarter of 2025. The report highlights continued growth in the U.S. market and operational improvements, reflecting the company’s commitment to expanding the footprint of its CADScor®System.

“Our first quarter results reflect an exciting beginning to 2025 and highlight the strength of our strategic push to expand our presence in the U. S. market,” said Aamir Mahmood, President & CEO of Acarix. “I am particularly proud of our collaboration with Geo-Med, a Service-Disabled Veteran-Owned Small Business, which is set to expand the reach of our CADScor®System to veterans across the country. In addition to this important partnership, we are honored to have received the 2025 Digital Innovation Award along with an honorable mention for Innovation in Cardiac Imaging at the Global Cardiovascular Awards in London. These recognitions not only highlight our commitment to delivering cutting-edge, non-invasive diagnostic solutions but also reinforce our promise to reduce unnecessary invasive procedures and improve patient care. Our strong revenue growth, fueled by a marked increase in U. S. system placements and a notable rise in patch sales, reflects our ongoing progress and the confidence the healthcare community has in us. We are committed to implementing our growth strategy, enhancing our operational efficiency, and fortifying partnerships that promote both clinical excellence and commercial success.”

Key Q1 2025 highlights:

  • Acarix has partnered with Geo-Med, a Service-Disabled Veteran-Owned Small Business, to expand the availability of its CADScor®System for veterans.
  • Acarix has received the 2025 Digital Innovation Award, along with an honorable mention for Innovation in Cardiac Imaging, at the Global Cardiovascular Awards in London for its CADScor®System.

First quarter 2025 compared to the same period in 2024:

  • Total revenue amounted to SEK 1,729 thousand, reflecting an 11% increase. Revenue from patches sold in the U. S. amounted to SEK 1,026 thousand, a 30% increase year-over-year.
  • Totally 20 CADScor Systems were delivered, a 54% increase over the same period in 2024. In the U. S., 19 CADScor Systems were installed, comprising 6 on consignment and 13 sold outright.
  • A total of 3,160 patches were sold, marking a 25% rise from the same timeframe in 2024. In the U. S., patch sales increased from 1,040 to 2,210 patches, marking a 104% growth
  • Gross profit was SEK 1,405 thousand, slightly down from SEK 1,413 thousand previously, with a gross margin of 81% (a decrease from 91%). Gross margin decreased by 10 percentage points this quarter mainly due to a one-time, strategically priced order for a key customer aimed at driving future high patch utilization.
  • Gross margin on patch sales is 93%.
  • Operating costs totaled SEK 15,437 thousand, a 6% decrease from SEK 16,340 thousand.
  • The reported loss was SEK -14,108 thousand, an improvement from the loss of SEK -14,930 thousand reported in the same timeframe last year.
  • Net cash flow for the period was SEK -11,767 thousand, compared to SEK 27,985 thousand during the same period last year.
  • Earnings per share were SEK -0.01, compared to SEK -0.02 in the previous year.
  • Cash and cash equivalents totaled SEK 45,048 thousand, a decrease from SEK 63,925 thousand on the same date last year, which included the completion of a rights issue amounting to SEK 46,598 thousand.

Webcast presentation of the Q1 interim report is available at 1:00 PM CET on: https://www.acarix.com/investor-presentations/

Link to the Acarix financial reports: https://www.acarix.com/for-investors/financial-reports-and-calendar